Therapeutic Advances in Gastroenterology最新文献

{"title":"Authors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.","authors":"Badr Al-Bawardy, Mohammed Nabil Quraishi","doi":"10.1177/17562848251328606","DOIUrl":"10.1177/17562848251328606","url":null,"abstract":"","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251328606"},"PeriodicalIF":3.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Randomized clinical trial: the effects of mirtazapine in functional dyspepsia patients.","authors":"Motij Kumar Dalai, Yogesh Bairwa, Sanjay Chandnani","doi":"10.1177/17562848251329433","DOIUrl":"10.1177/17562848251329433","url":null,"abstract":"","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251329433"},"PeriodicalIF":3.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn's disease.","authors":"Pauline Wils, Mathurin Fumery, Maria Nachury, Clara Yzet, Dilek Coban, Anthony Buisson","doi":"10.1177/17562848251326471","DOIUrl":"10.1177/17562848251326471","url":null,"abstract":"<p><strong>Background and objectives: </strong>We assessed the evolution of perianal lesions after switching intravenous (IV) to subcutaneous (SC) infliximab in patients with Crohn's disease (CD).</p><p><strong>Design: </strong>Subgroup analysis of REMSWITCH studies.</p><p><strong>Methods: </strong>We described the clinical and MRI outcomes of patients with a prior or current CD perianal lesions after the switch.</p><p><strong>Results: </strong>In REMSWITCH, 40 CD patients had a prior history of perianal lesions. No patient experienced a new perianal lesion (median follow-up = 18 months). Among the three patients (3/40, 7.5%) with clinically active perianal lesions at baseline, two patients had no more perianal lesions at month 18 while the last patient experienced lesions worsening. Another one with active perianal lesions on MRI but no symptom at baseline did not have any relapse within 18 months. Only one patient (1/40, 2.5%) had a perianal relapse (at month 25) with remission recapture after SC infliximab intensification.</p><p><strong>Conclusion: </strong>Switching from IV to SC infliximab in CD with perianal lesions is safe and feasible.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251326471"},"PeriodicalIF":3.9,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143732615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn's Disease.","authors":"José Luis Rueda García, Cristina Suárez-Ferrer, Clara Amiama Roig, Laura García Ramírez, Cristina García Rojas, Eduardo Martín-Arranz, Joaquín Poza Cordón, María Sánchez Azofra, Jesús Noci, Cristina Cubillo García, María Dolores Martín-Arranz","doi":"10.1177/17562848251324226","DOIUrl":"10.1177/17562848251324226","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic drug monitoring of adalimumab (ADA) is still controversial.</p><p><strong>Objectives: </strong>To study the association between ADA trough levels in the early stages of treatment with biological remission (BR) and drug survival in Crohn's disease (CD).</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>Patients treated with ADA with available trough levels at weeks 2 and 6 (after the first induction and maintenance dose, respectively) were included. Fecal calprotectin (Fcal) and C-reactive protein (CRP) were registered at baseline, week 24, and week 52. BR was defined as Fcal <200 µg/g and CRP <5 mg/dl. Treatment survival and the need for dose escalation were assessed at week 52. Receiver operating characteristic (ROC) curves were constructed to assess the diagnostic accuracy of ADA cutoff levels for BR. Quartile-specific comparisons were performed to evaluate differences in the proportion of patients achieving BR at weeks 24 and 52, drug survival, and dose escalation.</p><p><strong>Results: </strong>In all, 112 patients were included. ADA trough levels at week 6 were higher in patients achieving BR at week 24 (12.32 μg/ml vs 10.3 μg/ml, <i>p</i> = 0.0008), week 52 (12.3 μg/ml vs 10.8 μg/ml, <i>p</i> = 0.035), and in patients with 1-year treatment persistence (12.17 μg/ml vs 9.7 μg/ml, <i>p</i> = 0.03), but lower in patients requiring maintenance intensification (9.7 μg/ml vs 12.2 µg/ml, <i>p</i> < 0.0001). ADA week 6 trough levels >12.27 μg/ml predicted BR at week 24 with 79.7% specificity and 79.5% positive predictive value. Patients in the third quartile (Q3) and fourth quartile (Q4) of ADA levels at week 6 exhibited higher rates of BR at week 24, BR at week 52, 1-year drug survival, and less need for dose escalation (all <i>p</i>-values <0.05). In logistic regression, Q3 and Q4 of week 6 levels were significantly associated with BR at week 24 (<i>p</i> = 0.02 and <i>p</i> = 0.001); and week 6 Q4 with BR at week 52 (<i>p</i> = 0.02), treatment persistence (<i>p</i> = 0.03), and lower dose escalation (<i>p</i> = 0.004). ADA trough levels at week 2 did not show similar associations.</p><p><strong>Conclusion: </strong>ADA trough levels at week 6 are associated with BR at weeks 24 and 52, drug survival, and need for dose escalation in CD. However, ADA concentrations at week 2 failed to yield similar results.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251324226"},"PeriodicalIF":3.9,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life and burden of disease in a Mexican population with inflammatory bowel disease: an analysis of the RISE-MX trial.","authors":"Rosa M Miranda-Cordero, Francisco J Bosques-Padilla, Manuel Alejandro Martínez-Vázquez, Cristian Barajas-Maldonado, Mauricio M Rodriguez-Mendoza, Jesús K Yamamoto-Furusho","doi":"10.1177/17562848251318032","DOIUrl":"10.1177/17562848251318032","url":null,"abstract":"<p><strong>Background: </strong>Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) that have a negative impact on patient quality of life (QOL).</p><p><strong>Objective: </strong>To evaluate QOL, work productivity, use of healthcare resources, and medical costs in patients with IBD from the RISE-MX trial.</p><p><strong>Design: </strong>RISE-MX was a non-interventional, multicentric, cross-sectional, retrospective study conducted in a Mexican population with IBD.</p><p><strong>Methods: </strong>The 36-item Short Form Health Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ) were used to assess QOL. The burden of disease was analyzed using the Work Productivity and Activity Impairment Questionnaire (WPAI), healthcare resources use, and medical costs.</p><p><strong>Results: </strong>Of 326 subjects, 95 (29.1%) had CD, and 231 (70.8%) had UC. In patients with CD, 43 patients (45.3%) showed moderate-to-severe activity, and 42 (18.1%) had moderate-to-severe disease activity in patients with UC. In all SF-36 dimensions, a significant difference between moderate-to-severe and mild activity/in remission groups was observed in patients with UC, while in patients with CD, the difference between activity groups was significant only for physical functioning and social functioning dimensions. In patients with CD, a higher but non-significant IBDQ score difference between activity groups was observed while a statistical difference between activity groups was observed for all dimensions in UC patients. In WPAI, the total percentage for work impairment (absenteeism plus presenteeism) and the percentage of regular daily activity impairment were statistically significant between activity groups only for UC. The annual total costs (direct and indirect) per patient in CD were USD 19,757 (moderate-to-severe activity group) and USD 12,587 (mild activity/in remission group), while in patients with UC were USD 11,702 and USD 9144, respectively.</p><p><strong>Conclusion: </strong>Moderate-to-severe activity of disease was associated with a substantial impact on QOL, work productivity, and medical costs in Mexican patients with IBD. Total costs were higher for patients with CD than for patients with UC.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251318032"},"PeriodicalIF":3.9,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clipping closure length is a crucial factor for delayed bleeding after endoscopic papillectomy: a retrospective multicenter cohort study.","authors":"Yuki Fujii, Kazuyuki Matsumoto, Kiyoaki Ochi, Hitomi Himei, Ichiro Sakakihara, Eijiro Ueta, Tatsuya Toyokawa, Ryo Harada, Taiji Ogawa, Takeshi Tomoda, Hironari Kato, Ryosuke Sato, Taisuke Obata, Akihiro Matsumi, Kazuya Miyamoto, Daisuke Uchida, Shigeru Horiguchi, Koichiro Tsutsumi, Motoyuki Otsuka","doi":"10.1177/17562848251326450","DOIUrl":"10.1177/17562848251326450","url":null,"abstract":"<p><strong>Background: </strong>Bleeding is a serious and frequent adverse event that occurs during and after endoscopic papillectomy (EP). Previous studies have highlighted the effectiveness of preventive clipping closure of the resection site in preventing post-EP bleeding. However, the optimal length of closure remained unclear.</p><p><strong>Objectives: </strong>We aimed to clarify the optimal clipping length at the post-EP resection site to prevent delayed bleeding.</p><p><strong>Design: </strong>This study was a multicenter retrospective cohort study.</p><p><strong>Methods: </strong>We retrospectively analyzed patients who were consecutively admitted to nine high-volume centers for EP between November 2003 and October 2023. The primary outcome was the frequency of delayed bleeding based on the closure length. The optimal closure length rate of the resected site to prevent delayed bleeding was determined using a receiver operating characteristic curve. Secondary outcomes were the incidence, treatment outcomes, and risk factors for post-EP delayed bleeding.</p><p><strong>Results: </strong>A total of 130 patients who underwent EP were analyzed. Delayed bleeding was observed in 22 (17%) patients, occurring more frequently in cases without clipping closure than in those with clipping closure (28% (13/47) vs 11% (9/83); <i>p</i> = 0.014). Among 83 patients who underwent clipping closure, delayed bleeding occurred more frequently with a closure length rate <65% than in those with a closure rate ⩾65% (25% (5/20) vs 6% (4/63); <i>p</i> = 0.019). Multivariate analysis showed that a closure rate <65% was the risk factor for delayed bleeding (odds ratio, 6.3; 95% confidence interval, 1.2-33; <i>p</i> = 0.030) in cases with clipping.</p><p><strong>Conclusion: </strong>Clipping closure was effective in preventing delayed bleeding, and closure length rate ⩾65% of the resected site significantly reduced post-EP delayed bleeding.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251326450"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OLGA and OLGIM staging systems on the risk assessment of gastric cancer: a systematic review and meta‑analysis of prospective cohorts.","authors":"Harold Benites-Goñi, Dacio Cabrera-Hinojosa, Gonzalo Latorre, Adrian V Hernandez, Hugo Uchima, Arnoldo Riquelme","doi":"10.1177/17562848251325461","DOIUrl":"10.1177/17562848251325461","url":null,"abstract":"<p><strong>Background: </strong>The Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) are established classification systems used to evaluate atrophic gastritis and intestinal metaplasia, respectively.</p><p><strong>Objectives: </strong>We evaluated the association of OLGA and OLGIM scores and the risk of gastric cancer (GC) in only prospective cohort studies.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Data sources and methods: </strong>We systematically searched four databases for prospective cohorts that evaluated the use of OLGA and OLGIM staging systems in predicting the risk of GC. We primarily compared OLGA/OLGIM III-IV versus OLGA/OLGIM 0-II categories and GC events. Pooled risk ratios (RR) and absolute risk differences with their 95% confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>Eight studies were included (<i>n</i> = 12,526). The mean age of the patients ranged from 48.2 to 64.9 years. OLGA III-IV and OLGIM III-IV were associated with the development of GC in comparison to their 0-II categories (RR 32.31, 95% CI 9.14-114.21 and RR 12.38, 95% CI 5.75-26.65, respectively). OLGA III-IV and OLGIM III-IV were associated with an increase in the absolute risk of GC of 4% and 5%, respectively. The risk remained significant if we only included countries with high incidence of GC, and was greater if we excluded one study that included mostly patients with autoimmune gastritis. OLGA II and OLGIM II were associated with higher risk of high-grade dysplasia (HGD) and GC in comparison with OLGA 0-I and OLGIM 0-I, respectively.</p><p><strong>Conclusion: </strong>Higher stages in OLGA and OLGIM systems are associated with a significantly increased risk of developing HGD and GC, validating these scoring systems for the assessment of GC risk and the design of endoscopic surveillance programs.</p><p><strong>Trial prospero registration: </strong>CRD42024565771.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251325461"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: from pathogenesis to efficacy.","authors":"Chen Gu, Gengyu Sha, Binbin Zeng, Herong Cao, Yibo Cao, Dong Tang","doi":"10.1177/17562848251327167","DOIUrl":"10.1177/17562848251327167","url":null,"abstract":"<p><p>Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, with its progression intricately linked to gut microbiota dysbiosis. Disruptions in microbial homeostasis contribute to tumor initiation, immune suppression, and inflammation, establishing the microbiota as a key therapeutic target. Fecal microbiota transplantation (FMT) has emerged as a transformative approach to restore microbial balance, enhance immune responses, and reshape the tumor microenvironment. This review explores the mechanisms underlying FMT's therapeutic potential, evaluates its advantages over other microbiota-based interventions, and addresses challenges such as donor selection, safety concerns, and treatment standardization. Looking forward, the integration of FMT into personalized CRC therapies requires robust clinical trials and the identification of predictive biomarkers to optimize its efficacy and safety.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251327167"},"PeriodicalIF":3.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rediscovering histology - the application of artificial intelligence in inflammatory bowel disease histologic assessment.","authors":"Giovanni Santacroce, Irene Zammarchi, Olga Maria Nardone, Ivan Capobianco, Miguel Puga-Tejada, Snehali Majumder, Subrata Ghosh, Marietta Iacucci","doi":"10.1177/17562848251325525","DOIUrl":"10.1177/17562848251325525","url":null,"abstract":"<p><p>Integrating artificial intelligence (AI) into histologic disease assessment is transforming the management of inflammatory bowel disease (IBD). AI-aided histology enables precise, objective evaluations of disease activity by analysing whole-slide images, facilitating accurate predictions of histologic remission (HR) in ulcerative colitis and Crohn's disease. Additionally, AI shows promise in predicting adverse outcomes and therapeutic responses, making it a promising tool for clinical practice and clinical trials. By leveraging advanced algorithms, AI enhances diagnostic accuracy, reduces assessment variability and streamlines histological workflows in clinical settings. In clinical trials, AI aids in assessing histological endpoints, enabling real-time analysis, standardising evaluations and supporting adaptive trial designs. Recent advancements are further refining AI-aided digital pathology in IBD. New developments in multimodal AI models integrating clinical, endoscopic, histologic and molecular data pave the way for a comprehensive approach to precision medicine in IBD. Automated assessment of intestinal barrier healing - a deeper level of healing beyond endoscopic and HR - shows promise for improved outcome prediction and patient management. Preliminary evidence also suggests that AI applied to colitis-associated neoplasia can aid in the detection, characterisation and molecular profiling of lesions, holding potential for enhanced dysplasia management and organ-sparing approaches. Although challenges remain in standardisation, validation through randomised controlled trials and ethical considerations. AI is poised to revolutionise IBD management by advancing towards a more personalised and efficient care model, while the path to full clinical implementation may be lengthy. However, the transformative impact of AI on IBD care is already shining through.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251325525"},"PeriodicalIF":3.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient experiences with and adherence to Crohn's disease exclusion diet in Dutch Crohn's disease patients: a cohort study.","authors":"Fleur T R Wijers, Suzanne M C van Zundert, Charlotte M Verburgt, Nikki van der Kruk, Johan E Van Limbergen, Nicolette J Wierdsma","doi":"10.1177/17562848251323553","DOIUrl":"10.1177/17562848251323553","url":null,"abstract":"<p><strong>Background: </strong>Dietary therapy is commonly used as a treatment for Crohn's disease (CD). High dietary adherence is associated with achieving clinical remission. Crohn's disease exclusion diet (CDED) is a relatively new therapy in the management of CD.</p><p><strong>Objective: </strong>This publication aims to assess the first real-life patient experience with and adherence to Crohn's disease exclusion diet plus partial enteral nutrition (CDED + PEN) in Dutch children and adults with mild-to-moderate CD.</p><p><strong>Design: </strong>Interviews were performed with patients and/or caregivers prospectively after phases I, II, and III, and once after finishing therapy in a retrospective cohort.</p><p><strong>Methods: </strong>We obtained data on patient experiences with CDED and the accompanying Modulife patient support platform and assessed effectiveness from patients' and physicians' perspectives based on medical and clinical data obtained from the patient file. The interview contained open questions, 5-point Likert scales, and Net Promotor Scores (NPS).</p><p><strong>Results: </strong>Sixty-nine patients were included (52 pediatric and 17 adults). Approximately half of the patients in the prospective cohort and the majority (83%) of patients in the retrospective cohort would recommend CDED to others. Two-thirds of the patients would reconsider starting CDED again. A positive NPS (31) was given for recommending the support platform to others with the recipes feature as the most used and esteemed part. Median fecal calprotectin and C-reactive protein gradually decreased from baseline to 18 weeks of therapy in both children and adults. Two-thirds of the physicians assessed the diet as showing good effectiveness and would continue the dietary therapy at each phase of the diet.</p><p><strong>Conclusion: </strong>Many mild-to-moderate active CD patients may experience positive outcomes and have good experiences with the CDED + PEN dietary therapy and the associated Modulife patient support platform. This study might add valuable patient perspectives to the growing clinical use of CDED in managing CD.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251323553"},"PeriodicalIF":3.9,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}